BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

736 related articles for article (PubMed ID: 10866317)

  • 1. Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand.
    Mach N; Gillessen S; Wilson SB; Sheehan C; Mihm M; Dranoff G
    Cancer Res; 2000 Jun; 60(12):3239-46. PubMed ID: 10866317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the functional properties of murine dendritic cells generated in vivo with Flt3 ligand, GM-CSF and Flt3 ligand plus GM-SCF.
    Daro E; Butz E; Smith J; Teepe M; Maliszewski CR; McKenna HJ
    Cytokine; 2002 Feb; 17(3):119-30. PubMed ID: 11895330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma.
    Soiffer R; Hodi FS; Haluska F; Jung K; Gillessen S; Singer S; Tanabe K; Duda R; Mentzer S; Jaklitsch M; Bueno R; Clift S; Hardy S; Neuberg D; Mulligan R; Webb I; Mihm M; Dranoff G
    J Clin Oncol; 2003 Sep; 21(17):3343-50. PubMed ID: 12947071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dendritic cells genetically engineered to simultaneously express endogenous tumor antigen and granulocyte macrophage colony-stimulating factor elicit potent therapeutic antitumor immunity.
    Nakamura M; Iwahashi M; Nakamori M; Ueda K; Matsuura I; Noguchi K; Yamaue H
    Clin Cancer Res; 2002 Aug; 8(8):2742-9. PubMed ID: 12171908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect.
    Choi KJ; Kim JH; Lee YS; Kim J; Suh BS; Kim H; Cho S; Sohn JH; Kim GE; Yun CO
    Gene Ther; 2006 Jul; 13(13):1010-20. PubMed ID: 16525479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of T-cell apoptosis in rats by genetically engineered glioma cells expressing granulocyte-macrophage colony-stimulating factor and B7.1.
    Tseng SH; Chen Y; Chang CJ; Tai KF; Lin SM; Hwang LH
    Clin Cancer Res; 2005 Feb; 11(4):1639-49. PubMed ID: 15746069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combinational FLt3 ligand and granulocyte macrophage colony-stimulating factor treatment promotes enhanced tumor infiltration by dendritic cells and antitumor CD8(+) T-cell cross-priming but is ineffective as a therapy.
    Berhanu A; Huang J; Alber SM; Watkins SC; Storkus WJ
    Cancer Res; 2006 May; 66(9):4895-903. PubMed ID: 16651446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer.
    Simons JW; Mikhak B; Chang JF; DeMarzo AM; Carducci MA; Lim M; Weber CE; Baccala AA; Goemann MA; Clift SM; Ando DG; Levitsky HI; Cohen LK; Sanda MG; Mulligan RC; Partin AW; Carter HB; Piantadosi S; Marshall FF; Nelson WG
    Cancer Res; 1999 Oct; 59(20):5160-8. PubMed ID: 10537292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
    Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
    Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel membrane-bound GM-CSF vaccines for the treatment of cancer: generation and evaluation of mbGM-CSF mouse B16F10 melanoma cell vaccine.
    Yei S; Bartholomew RM; Pezzoli P; Gutierrez A; Gouveia E; Bassett D; Soo Hoo W; Carlo DJ
    Gene Ther; 2002 Oct; 9(19):1302-11. PubMed ID: 12224013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor effects of granulocyte-macrophage colony-stimulating factor production by melanoma cells.
    Armstrong CA; Botella R; Galloway TH; Murray N; Kramp JM; Song IS; Ansel JC
    Cancer Res; 1996 May; 56(9):2191-8. PubMed ID: 8616871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Granulocyte-macrophage colony-stimulating factor (GM-CSF) secreted by cDNA-transfected tumor cells induces a more potent antitumor response than exogenous GM-CSF.
    Shi FS; Weber S; Gan J; Rakhmilevich AL; Mahvi DM
    Cancer Gene Ther; 1999; 6(1):81-8. PubMed ID: 10078967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intensified antitumor immunity by a cancer vaccine that produces granulocyte-macrophage colony-stimulating factor plus interleukin 4.
    Wakimoto H; Abe J; Tsunoda R; Aoyagi M; Hirakawa K; Hamada H
    Cancer Res; 1996 Apr; 56(8):1828-33. PubMed ID: 8620500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
    Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
    Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Injection of DNA encoding granulocyte-macrophage colony-stimulating factor recruits dendritic cells for immune adjuvant effects.
    Bowne WB; Wolchok JD; Hawkins WG; Srinivasan R; Gregor P; Blachere NE; Moroi Y; Engelhorn ME; Houghton AN; Lewis JJ
    Cytokines Cell Mol Ther; 1999 Dec; 5(4):217-25. PubMed ID: 10850386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Flt3 ligand promotes myeloid dendritic cell differentiation of human hematopoietic progenitor cells: possible application for cancer immunotherapy.
    Harada S; Kimura T; Fujiki H; Nakagawa H; Ueda Y; Itoh T; Yamagishi H; Sonoda Y
    Int J Oncol; 2007 Jun; 30(6):1461-8. PubMed ID: 17487367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.
    Galea-Lauri J; Wells JW; Darling D; Harrison P; Farzaneh F
    Cancer Immunol Immunother; 2004 Nov; 53(11):963-77. PubMed ID: 15146294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Granulocyte-macrophage colony-stimulating factor and interleukin-2 fusion cDNA for cancer gene immunotherapy.
    Stagg J; Wu JH; Bouganim N; Galipeau J
    Cancer Res; 2004 Dec; 64(24):8795-9. PubMed ID: 15604233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polarization of naive T cells into Th1 or Th2 by distinct cytokine-driven murine dendritic cell populations: implications for immunotherapy.
    Feili-Hariri M; Falkner DH; Morel PA
    J Leukoc Biol; 2005 Sep; 78(3):656-64. PubMed ID: 15961574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.